TABLE 2.

Baseline demographic and clinical characteristics.

Variables	Baseline (n = 283) (100.0%)	With 1-month (n = 79) (27.9%)	Without 1-month (n = 204) (72.1%)	p-value
Age (years)	61.5 ± 8.9	60.5 ± 7.3	61.9 ± 9.5	0.186
Gender (male)	141 (49.8%)	39 (49.4%)	102 (50.0%)	0.924
Formal education (years)	8.9 ± 4.7	9.6 ± 3.7	8.6 ± 5.0	0.259
Age at onset (years)	59.2 ± 8.9	58.5 ± 7.4	59.5 ± 9.4	0.319
Duration of symptom onset (years)	2.3 ± 2.3	2.1 ± 1.5	2.4 ± 2.5	0.859
UPDRS part II	9.3 ± 5.5	8.3 ± 4.5	9.7 ± 5.8	0.062
UPDRS part III	22.5 ± 11.6	22.6 ± 11.7	22.4 ± 11.7	0.890
Modified H-Y stage	1.6 ± 0.6	1.5 ± 0.5	1.6 ± 0.6	0.764
MMSE	26.7 ± 3.9	27.0 ± 3.1	26.6 ± 4.1	0.758
MoCA	22.5 ± 5.2	22.5 ± 4.0	22.5 ± 5.6	0.283
HAMD	10.1 ± 8.3	9.0 ± 5.2	10.5 ± 9.2	0.948
HAMA	7.8 ± 6.5	6.4 ± 4.1	8.3 ± 7.2	0.171
PDSS	121.7 ± 24.2	123.7 ± 26.4	120.9 ± 23.3	0.154
NMSQuest	8.6 ± 4.6	8.4 ± 3.6	8.7 ± 5.0	0.973

Data are presented as the mean ± SD and n (%). Comparisons of demographic and clinical features at baseline between patients with and without 1-month follow-up assessments. Univariate p-values were calculated using two-sample t-test, Mann–Whitney U-test, or Chi-squared test. UPDRS, unified Parkinson’s disease rating scale; H-Y, Hoehn and Yahr; MMSE, Mini-mental state examination; MoCA, Montreal Cognitive Assessment; HAMD, Hamilton Depression Scale; HAMA, Hamilton Anxiety Scale; PDSS, Parkinson disease sleep scale; NMSQuest, non-motor symptoms questionnaire.